Skip to main content

NUEVOS CONOCIMIENTOS SOBRE EL PAPEL DE LA NADPH OXIDASA NOX4 EN HEPATOCARCINOGENESIS. RELEVANCIA EN LA VIAS DE SEÑALIZACION DEL TGF-BETA Y DEL RECEPTOR DEL EGF.

SAF2015-64149-R

•
Funding agency name Ministerio de Economía y Competitividad
Funding agency acronym MINECO
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2015
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Management unit Dirección General de Investigación Científica y Técnica
Beneficiary centre FUNDACIO INSTITUT D INVESTIGACIO BIOMEDICA DE BELLVITGE (IDIBELL)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

BULERIA. Repositorio Institucional de la Universidad de León
Publication Artículo científico (JournalArticle)

Anti-miR-518d-5p overcomes liver tumor cell death resistance through mitochondrial activity

  • Fernández Tussy, Pablo
  • Rodríguez Agudo, Rubén
  • Fernández Ramos, David
  • Barbier Torres, Lucía
  • Zubiete Franco, Imanol
  • Davalillo, Sergio López de
  • Herráez, Elisa
  • Goikoetxea Usandizaga, Naroa
  • Lachiondo Ortega, Sofía
  • Simón, Jorge
  • Lopitz Otsoa, Fernando
  • Gutiérrez de Juan, Virginia
  • McCain, Misti V.
  • Perugorría, María J.
  • Mabe, Jon
  • Navasa Mayo, Nicolás
  • Rodrigues, Cecilia M. P.
  • Fabregat, Isabel
  • Boix, Loreto
  • Sapena, Víctor
  • Anguita, Juan
  • Lu, Shelly C.
  • Mato, José M.
  • Banales, Jesus M.
  • Villa, Erica
  • Reeves, Helen L.
  • Bruix, Jordi
  • Reig, María
  • Marín, José J. G.
  • Delgado, Teresa C.
  • Martínez Chantar, María L.
[EN]Dysregulation of miRNAs is a hallmark of cancer, modulating oncogenes, tumor suppressors, and drug responsiveness. The multi-kinase inhibitor sorafenib is one of the first-line drugs for advanced hepatocellular carcinoma (HCC), although the outcome for treated patients is heterogeneous. The identification of predictive biomarkers and targets of sorafenib efficacy are sorely needed. Thus, selected top upregulated miRNAs from the C19MC cluster were analyzed in different hepatoma cell lines compared to immortalized liver human cells, THLE-2 as control. MiR-518d-5p showed the most consistent upregulation among them. Thus, miR-518d-5p was measured in liver tumor/non-tumor samples of two distinct cohorts of HCC patients (n = 16 and n = 20, respectively). Circulating miR-518d-5p was measured in an independent cohort of HCC patients receiving sorafenib treatment (n = 100), where miR-518d-5p was analyzed in relation to treatment duration and patient’s overall survival. In vitro and in vivo studies were performed in human hepatoma BCLC3 and Huh7 cells to analyze the effect of miR-518d-5p inhibition/overexpression during the response to sorafenib. Compared with healthy individuals, miR-518d-5p levels were higher in hepatic and serum samples from HCC patients (n = 16) and in an additional cohort of tumor/non-tumor paired samples (n = 20). MiR-518d-5p, through the inhibition of c-Jun and its mitochondrial target PUMA, desensitized human hepatoma cells and mouse xenograft to sorafenib-induced apoptosis. Finally, serum miR-518d-5p was assessed in 100 patients with HCC of different etiologies and BCLC-stage treated with sorafenib. In BCLC-C patients, higher serum miR-518d-5p at diagnosis was associated with shorter sorafenib treatment duration and survival. Hence, hepatic miR-518d-5p modulates sorafenib resistance in HCC through inhibition of c-Jun/PUMA-induced apoptosis. Circulating miR-518d-5p emerges as a potential lack of response biomarker to sorafenib in BCLC-C HCC patients., SI, This work was supported by grants from NIH (US Department of Health and Human services) R01CA172086 (to S.C.L., J.M.M. and M.L.M.-C.) and P01CA233452 (to S.C.L.), Gobierno Vasco-Departamento de Salud 2013111114 (to M.L.M.-C), MINECO: SAF2017-87301-R, SAF2014-52097-R, RTI2018-096759-A-100, SAF2016-75197-R and SAF2015-64149-R, integrated in the Plan Estatal de Investigación Cientifica y Técnica e Innovación 2017-2020 cofounded by FEDER funds/Development Fund—a way to build Europe (to M.L.M.-C., J.M.M., T.C.D., J.J.G.M., and I.F., respectively), Fondo de Investigaciones Sanitarias, Instituto de Salud Carlos III, Spain: PI16/00598 and PI19/00819 (to J.J.G.M.), PI15/01132 and PI18/01075 (to J.M.B.), PI14/00399 and PI17/00022 (to M.J.P.), PI18/0358 (to M.R.), BIOEF (Basque Foundation for Innovation and Health Research): EITB Maratoia BIO15/CA/014 and BIO15/CA/016/BD (to M.L.M.-C and J.M.B., respectively); Mitotherapeutix (to M.L.M.-C), Consejería de Educación, Junta de Castilla y León: SA063P17 (J.J.G.M.), Asociación Española Contra el Cáncer (T.C. D, P.F.-T., and M.L.M-C), Basque Government Postdoctoral Program (P.F.-T.), Daniel Alagille award from EASL (to T.C.D.), Asociación Española contra el Cáncer, Canceres raros (M.L.M.-C., J.M.B., and J.J.G.M.), La Caixa Foundation (to M.L.M.-C. and J.M.B.), Ayudas Fundación BBVA a equipos de Investigación Científica 2018 (to M.L.M.-C.), Fondo Europeo de Desarrollo Regional’ (FEDER) (to J.M.B.); CIBERehd, Spain (to J.M.B.); IKERBASQUE, Basque foundation for Science, Spain (to J.M.B.), Department of Health of the Basque Country (2017111010) (to J.M.B.), Euskadi RIS3 (2019222054, 2020333010) (to J.M.B.); Department of Industry of the Basque Country (J.M.B.: Elkartek: KK-2020/00008) (to J.M.B.), Ayudas para apoyar grupos de investigación del sistema Universitario Vasco IT971, Instituto de Salud Carlos III PI18/00768 (J.B.), AECC PI044031 (J.B.), Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement 2014 SGR 605 (J.B.), WCR (AICR) 16-0026 (J.B.), Programma di ricerca Regione-Università 2007–2009 and 2011–2012, Regione Emilia- Romagna (E.V.).
Docta Complutense
Publication Artículo científico (JournalArticle)

A Signaling Crosstalk between BMP9 and HGF/c-Met Regulates Mouse Adult Liver Progenitor Cell Survival

  • Addante, Annalisa
  • Roncero Romero, Cesáreo
  • Lazcanoiturburu, Nerea
  • Méndez, Rebeca
  • Almale Del Barrio, Laura
  • García-Álvaro, María
  • Dijke, Peter ten
  • Fabregat Romero, María Isabel
  • Herrera González, Blanca María
  • Sánchez Muñoz, Aranzazu
During chronic liver disease, hepatic progenitor cells (HPC, oval cells in rodents) become activated, proliferate, and differentiate into cholangiocytes and/or hepatocytes contributing to the final outcome of the regenerative process in a context-dependent fashion. Here, we analyze the crosstalk between the hepatocyte growth factor (HGF)/c-Met signaling axis, key for liver regeneration, and bone morphogenetic protein (BMP)9, a BMP family ligand that has emerged as a critical regulator of liver pathology. Our results show that HGF/c-Met signaling blocks BMP9-mediated apoptotic cell death, while it potentiates small mothers against decapentaplegic (SMAD)1 signaling triggered by BMP9 in oval cells. Interestingly, HGF-induced overactivation of SMAD1, -5, -8 requires the upregulation of TGF-β type receptor activin receptor-like kinase (ALK)1, and both ALK1 and SMAD1 are required for the counteracting effect of HGF on BMP9 apoptotic activity. On the other hand, we also prove that BMP9 triggers the activation of p38MAPK in oval cells, which drives BMP9-apoptotic cell death. Therefore, our data support a model in which BMP9 and HGF/c-Met signaling axes establish a signaling crosstalk via ALK1 that modulates the balance between the two pathways with opposing activities, SMAD1 (pro-survival) and p38 mitogen-activated protein kinases (p38MAPK; pro-apoptotic), which determines oval cell fate. These data help delineate the complex signaling network established during chronic liver injury and its impact on the oval cell regenerative response.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The NADPH oxidase NOX4 regulates redox and metabolic homeostasis preventing HCC progression

  • Peñuelas-Haro, Irene
  • Espinosa-Sotelo, Rut
  • Crosas-Molist, Eva
  • Herranz-Itúrbide, Macarena
  • Caballero-Díaz, Daniel
  • Alay, Ania
  • Solé, Xavier
  • Ramos, Emilio
  • Serrano, Teresa
  • Martínez-Chantar, María Luz
  • Knaus, Ulla G.
  • Cuezva, José M.
  • Zorzano, Antonio
  • Bertran, Esther
  • Fabregat, Isabel
Background and aims: The NADPH oxidase NOX4 plays a tumor-suppressor function in HCC. Silencing NOX4 confers higher proliferative and migratory capacity to HCC cells and increases their in vivo tumorigenic potential in xenografts in mice. NOX4 gene deletions are frequent in HCC, correlating with higher tumor grade and worse recurrence-free and overall survival rates. However, despite the accumulating evidence of a protective regulatory role in HCC, the cellular processes governed by NOX4 are not yet understood. Accordingly, the aim of this work was to better understand the molecular mechanisms regulated by NOX4 in HCC in order to explain its tumor-suppressor action. Approach and results: Experimental models: cell-based loss or gain of NOX4 function experiments, in vivo hepatocarcinogenesis induced by diethylnitrosamine in Nox4-deficient mice, and analyses in human HCC samples. Methods include cellular and molecular biology analyses, proteomics, transcriptomics, and metabolomics, as well as histological and immunohistochemical analyses in tissues. Results identified MYC as being negatively regulated by NOX4. MYC mediated mitochondrial dynamics and a transcriptional program leading to increased oxidative metabolism, enhanced use of both glucose and fatty acids, and an overall higher energetic capacity and ATP level. NOX4 deletion induced a redox imbalance that augmented nuclear factor erythroid 2-related factor 2 (Nrf2) activity and was responsible for MYC up-regulation. Conclusions: Loss of NOX4 in HCC tumor cells induces metabolic reprogramming in a Nrf2/MYC-dependent manner to promote HCC progressio, Supported by Agencia Estatal de Investigación, Ministerio de Ciencia e Innovación, Spain (co‐funded by European Regional Development Fund ERDF, a way to build Europe) (SAF2015‐64149‐R, RTI2018‐094079‐B‐100, PID2021‐122551OB‐I00, PID2019‐106209RB‐I00, PID2019‐108674RB‐100, and RED2018‐102576‐T); FPI fellowships (BES‐2016‐077564 and PRE2019‐089144); the Generalitat de Catalunya (2017SGR1015); Science Foundation Ireland (16/IA/4501); CIBER, National Biomedical Research Institute, which is funded by the Instituto de Salud Carlos III, Spain; CERCA Programme/Generalitat de Catalunya; and an ICREA “Academia” Award (Generalitat de Catalunya)
Docta Complutense
Publication Artículo científico (JournalArticle)

Clathrin switches transforming growth factor-β role to pro-tumorigenic in liver cancer

  • Caballero-Díaz, Daniel
  • Bertran, Esther
  • Peñuelas-Haro, Irene
  • Moreno-Càceres, Joaquim
  • Malfettone, Andrea
  • López-Luque, Judit
  • Addante, Annalisa
  • Herrera González, Blanca María
  • Sánchez Muñoz, Aranzazu
  • Alay, Ania
  • Solé, Xavier
  • Serrano, Teresa
  • Ramos, Emilio
  • Fabregat Romero, María Isabel
Background & Aims: Upon ligand binding, tyrosine kinase receptors, such as epidermal growth factor receptor (EGFR), are recruited into clathrin-coated pits for internalization by endocytosis, which is relevant for signalling and/or receptor degradation. In liver cells, transforming growth factor-b (TGFb) induces both pro- and anti-apoptotic signals; the latter are mediated by the EGFR pathway. Since EGFR mainly traffics via clathrin-coated vesicles, we aimed to analyse the potential role of clathrin in TGF-b-induced signalling in liver cells and its relevance in liver cancer. Methods: Real-Time PCR and immunohistochemistry were used to analyse clathrin heavy-chain expression in human (CLTC) and mice (Cltc) liver tumours. Transient knockdown (siRNA) or overexpression of CLTC were used to analyse its role on TGF-b and EGFR signalling in vitro. Bioinformatic analysis was used to determine the effect of CLTC and TGFB1 expression on prognosis and overall survival in patients with hepatocellular carcinoma (HCC). Results: Clathrin expression increased during liver tumorigenesis in humans and mice. CLTC knockdown cells responded to TGF-b phosphorylating SMADs (canonical signalling) but showed impairment in the anti-apoptotic signals (EGFR transactivation). Experiments of loss or gain of function in HCC cells reveal an essential role for clathrin in inhibiting TGF-b-induced apoptosis and upregulation of its pro-apoptotic target NOX4. Autocrine TGF-b signalling in invasive HCC cells upregulates CLTC expression, switching its role to pro-tumorigenic. A positive correlation between TGFB1 and CLTC was found in HCC cells and patients. Patients expressing high levels of TGFB1 and CLTC had a worse prognosis and lower overall survival. Conclusions: This work describes a novel role for clathrin in liver tumorigenesis, favouring non-canonical pro-tumorigenic TGF-b pathways. CLTC expression in human HCC samples could help select patients that would benefit from TGF-b-targeted therapy. Lay summary: Clathrin heavy-chain expression increases during liver tumorigenesis in humans (CLTC) and mice (Cltc), altering the cellular response to TGF-b in favour of anti-apoptotic/ pro-tumorigenic signals. A positive correlation between TGFB1 and CLTC was found in HCC cells and patients. Patients expressing high levels of TGFB1 and CLTC had a worse prognosis and lower overall survival. CLTC expression in HCC human samples could help select patients that would benefit from therapies targeting TGF-b.